CBD Proves to be an Effective Therapy for PTSD

Since the discovery that the endocannabinoid system is involved in emotional memory processing, researchers have begun to examine whether cannabidiol, or CBD, could be an effective therapeutic treatment option for those suffering from PTSD.

Post-traumatic stress disorder, or PTSD, is a psychiatric disorder that will affect approximately 10% of people at some point in their lives.  PTSD can occur when people fail to acclimate following a traumatic experience.  PTSD can affect people of all ages.  Since the discovery that the endocannabinoid system is involved in emotional memory processing, researchers have begun to examine whether cannabidiol, or CBD, which has a regulatory effect on the endocannabinoid system, could be an effective therapeutic treatment option for those suffering from PTSD.

CBD is one of the many molecular compounds of the hemp plant.  CBD is extracted from industrial hemp and does not share the psychoactive properties of THC.  Preclinical studies performed in rats showed that CBD had the ability to eradicate negative memories, as well as, block them from returning.  The preclinical trials were promising enough to justify treating individuals affected by PTSD with cannabidiol and the results were similarly positive.

To read more about the Brazilian medical study, referenced in this article, “Recent studies have confirmed the ability of CBD to alter important aspects of aversive memories in humans and promote significant improvements in the symptomatology of PTSD,” please click here.

Nectar CBD offers organic CBD oil for sale in all 50 states.  You can buy CBD-rich hemp oil online at our website, www.BuyNectarCBD.com.  Nectar CBD provides the purest CBD distillate products available on the market, cultivated from sustainably-grown Colorado hemp plants and manufactured with precision.

The Most Effective Delivery Method of CBD for Dogs

A study by Colorado State University sought to determine the pharmacokinetics of cannabidiol (CBD) in dogs.

A study performed by the Department of Clinical Sciences at Colorado State University sought to determine the pharmacokinetics of cannabidiol (CBD) in dogs. Pharmacokinetics examines the bodily absorption, distribution, metabolism and excretion of drugs.

The study performed involved the participation of 30 healthy dogs. Each dog was treated with one of three CBD treatments: oral CBD oil beads, oral CBD oil or CBD skin cream. The dosages were 75mg or 150mg every 12 hours for 6 weeks, with the CBD treatments being dose-proportional. Cannabidiol levels in the dogs’ blood were measured over the course of the 6-week study. The experiment demonstrated that that oral dosages of CBD oil had the best pharmacokinetic profile, as this delivery method demonstrated the highest concentrations of cannabidiol retention in the dogs’ system.

To learn more about the Colorado State University canine study referenced above, please see the link here.

Nectar CBD offers CBD-rich hemp oil pet drops, Nectar 300 Pet Drops and Nectar 600 Pet Drops, which are hemp extract formulated in organic MCT coconut oil. Nectar CBD provides organic CBD oil for sale in Colorado and offers an entire line of CBD products for pets, including pet treats.

Study Shows Cannabidiol Inhibits Lung Cancer Cell Invasion

CBD could help stop the spread of cancer cells in the lungs and support lung function in general.

Focusing on the health of our lungs is often a neglected practice, and yet, according to the American Lung Association, approximately 415,000 Americans living today have been diagnosed with lung cancer. Lung cancer is the most common cancer worldwide, accounting for 1.8 million new cases and 1.6 million deaths in 2012 (1). The search for natural remedies to prevent and combat cancer cells in the lungs has led to research on the potential beneficial properties of CBD.

In 2009, the work of researchers studying the effect of cannabinoids against cancer cell invasion was published in the Federation of American Societies for Experimental Biology. Their results showed that cannabidiol upregulated a compound called ICAM-1 in a clinically significant manner, which then led to a subsequent decrease in cancer cell invasiveness.

Given that lung cancer is the most common cancer worldwide and that sufficient oxygen flow is a key factor for producing cellular energy, this study becomes extremely promising and warrants deeper study into how CBD can help stop the spread of cancer cells in the lungs and support lung function in general. You can learn more about this study at: https://www.ncbi.nlm.nih.gov/pubmed/22198381.

Neuroimaging Study Shows Anxiolytic (Anxiety-Reducing) Properties of CBD

The study confirmed that CBD does in fact seem to possess anti-anxiety properties, which are triggered by CBD’s effect on the limbic and paralimbic brain areas.

There are countless reports of cannabidiol, or CBD, being used as an effective anti-anxiety therapy, but the physical changes that cause CBD to act as an anxiolytic had not been previously studied. Researchers at the University of São Paulo in Brazil conducted an experiment to determine the physical cause of anxiolytic response by utilizing neuroimaging, in conjunction with, subjective testing.

The study consisted of 10 healthy male volunteers, randomly divided into two groups of five, over two separate sessions.  The first test group of 5 men received an oral CBD treatment of 400mg, while the second group received a placebo.  Neuroimage testing was performed 90 minutes after dosing, along with, a subjective test, known as the Visual Analogue Mood Scale.  One week later, the process was repeated, but with the subjects receiving the treatment that they had not received in the previous session.

The results of the Visual Analogue Mood Scale showed that “CBD significantly decreased subjective anxiety and increased mental sedation, while the placebo did not induce significant changes.” Assessment of the neuroimaging showed a definite clustering of brain cells in the amygdala-hippocampal, hypothalamus and the left posterior cingulate gyrus, all contributing to the anxiolytic effects present during the subjective testing. The study confirmed that CBD does in fact seem to possess anti-anxiety properties, which are triggered by CBD’s effect on the limbic and paralimbic brain areas.

To read more about the study quoted above, please see here.

CBD Reduces Brain Damage in a Rat Model of Neonatal Arterial Ischemic Stroke

In April 2017, European researchers published a study in the Journal of Neuropharmacology that demonstrated the neuroprotective effect of CBD in a rat model of AIS.

Neonatal Arterial Ischemic Stroke, or Neonatal AIS, refers to a lack of blood flow to certain parts of a newborn child’s brain due to the narrowing of an artery or a blood clot in an artery. According to The International Pediatric Stroke Study, “Neonatal AIS has emerged as a leading cause of perinatal brain injury, cerebral palsy and lifelong disability.” (1) Unfortunately, there is currently no known effective treatment.

In April 2017, European researchers published a study in the Journal of Neuropharmacology that demonstrated the neuroprotective effect of CBD in a rat model of AIS. According to the scientists performing the study, CBD administration led to:

  • long-term functional recovery
  • reduced neuronal loss
  • reduced astrogliosis, which is an abnormal increase in the number of astrocytes due to the destruction of nearby neurons
  • modulation of apoptosis (death of cells), metabolic derangement, excitotoxicity and neuro-inflammation
  • improved neurobehavioral function regarding strength, hemiparesis (weakness or the inability to move one side of the body), coordination and sensorimotor performance

Given there is no current treatment for this serious and life altering type of childhood stroke, the results of this study are extremely promising and warrant deeper investigation into CBD for its neurological health benefits. You can learn more about this study at: https://www.ncbi.nlm.nih.gov/pubmed/28012949.

CBD Beneficial in Reducing Drop Seizures for Lennox-Gastaut Syndrome Drop Seizures

Cannabidiol has demonstrated, in studies, to have antiepileptic properties and has had widespread success as a treatment therapy for various types of seizure disorders.

Lennox-Gastaut Syndrome (LGS) is severe form of epilepsy which often begins in early childhood.  One type of seizure that is common with Lennox-Gastaut Syndrome is a drop seizure, where the patient temporarily loses all muscle function, loses consciousness and collapses.  It is not uncommon for those suffering from drop seizures to experience multiple episodes per week.  Cannabidiol, or CBD, has demonstrated, in studies, to have antiepileptic properties and has had widespread success as a treatment therapy for various types of seizure disorders.

In a collaborative study involving 30 clinics, 225 people with Lennox-Gastaut syndrome participated in a double-blind study to evaluate the safety and efficacy of adding cannabidiol to their current conventional antiepileptic medication.  Patients ranged in age from 2 to 55 years old and were experiencing two or more drop seizures per week. 76 patients received 20mg of CBD, 73 patients received 10mg CBD and the remaining 76 received an equal volume of a placebo substance, each daily, for 14 weeks.  The results showed a definite decrease in drop seizures for those patients receiving CBD: a 41.9% decrease for the group receiving 20mg cannabidiol per day and a 37.2% decrease for the group receiving 10mg cannabidiol per day.  Compared to the placebo group, whose reduction was 17.2%, the study demonstrated a significant reduction in the number of drop seizures for those receiving CBD, in addition to, their current antiepileptic medications.

We are excited to review ongoing research which demonstrates the positive effects of cannabidiol on varying disorders and medical conditions.  To read more about the study mentioned above, please see here.

In-Vitro Study Shows Anti-inflammatory Properties of CBD for Allergic Contact Dermatitis

CBD was shown to elevate levels of anandamide, resulting in anti-inflammatory and anti-allergenic properties.

Dermatitis is a common problem with a wide range of causes; it involves excessive pro-inflammatory compounds in the skin, often resulting in an itchy rash or red swollen skin. Allergic Contact Dermatitis (ACD) involves the immune system overreacting to certain substances, sometimes even in very small amounts, that normally shouldn’t cause a reaction. Some of the most common examples are:

  • Dander from dogs, cats and other animals
  • Plant oils and compounds such as poison ivy and latex
  • Certain metals such as nickel and gold, often found in jewelry
  • Fragrances found in body and home products such as perfumes, deodorants, shampoos and cleaning products
  • Topical antibiotics common in first aid creams and ointments
  • Preservatives such as Quaternium 15, frequently found in cosmetic and industrial products

In June of 2018, research scientists created an in-vitro (meaning it was performed outside of a living organism, such as in a test tube or culture dish) model of ACD and measured the release of pro-inflammatory compounds in the presence of CBD and other phytocannabinoids. Based on their findings, CBD was shown to elevate levels of anandamide, an endogenous cannabinoid that activates CB2 receptors (such as along immune cells in the blood), resulting in anti-inflammatory and anti-allergenic properties. It was also shown to have no cytotoxic effect.

This study is very promising and warrants deeper investigation of topical CBD on humans and animals for relieving the symptoms of ACD. You can learn more about the study, found in the Journal of Pharmacology and Experimental Therapeutics, at: http://jpet.aspetjournals.org/content/365/3/652.

CBD Effective at Managing RBD Sleep Disorder in Parkinson’s Patients

The study confirmed that CBD was successfully able to control RBD symptoms in Parkinson’s patients and was published in the Journal of Clinical Pharmacy and Therapeutics.

One of the many symptoms of Parkinson’s Disease is rapid eye movement sleep behavior disorder or RBD.  RBD occurs during normal rapid eye movement (REM) sleep patterns, but prevents the patient from experiencing the usual muscle paralysis occurring during REM sleep.  Throughout REM sleep, people experience vivid dreams and the muscle paralysis serves to keep the person still and resting.  During RBD, patients can physically act out their dreams, to some extent, leading to possible injury to themselves and/or their partners.  Yelling, swearing, pushing, punching and kicking during sleep are all common behaviors for the RBD sleep disorder.  Cannabidiol (CBD) is one of the major components of the hemp plant; it has proven to have a diverse pharmacological profile, while absent of psychoactive effects, which has led to extensive research as a treatment therapy option for various diseases and disorders.

Researchers at the University of São Paulo in the Department of Neuroscience and Behavior, in Brazil, tested the effects of cannabidiol on Parkinson’s patients suffering from RBD sleep disorder.  Patients received either 75mg or 300mg of CBD per day for a 6-week period. During the case study, all patients showed a “prompt and substantial reduction in the frequency of RBD-related events without side effects.”  Their study confirmed that CBD was successfully able to control RBD symptoms in Parkinson’s patients and was published in the Journal of Clinical Pharmacy and Therapeutics.

As the research surrounding this remarkable compound continues to progress, we look forward to reviewing the research. To read the full text of the study cited in this article, please see here.

CBD May Stop the Spread of Ovarian Cancer

Sullivan University College of Pharmacy in Louisville, Kentucky, researched the effects of CBD therapy on ovarian cancer cells.

Ovarian cancer accounts for approximately 2% of all new cancer cases diagnosed each year.  When diagnosed early, before the onset of metastasis, which is the migration of cancer cells throughout the body, ovarian cancer is fairly treatable.  There is currently an urgent need, however, to find an effective ovarian cancer treatment to prevent metastasis.  Cannabidiol (CBD), one of the main components of hemp, has been proven to be an effective anti-cancer treatment against multiple types of cancers in various studies.

In 2017, Sullivan University College of Pharmacy in Louisville, Kentucky, researched the effects of CBD therapy on ovarian cancer cells.  When two types of cancer cell lines were treated with hemp extract containing CBD, cancer cell migration was reduced.  In one line, metastasis was significantly slowed across all CBD dosages tested.  The other line, when treated with 2.5-3.2 micrometers of CBD per cell, showed a decrease in cell migration similar to the chemotherapy drug Cisplatin. Based on their results, CBD showed definite anti-metastatic properties on ovarian cancer cells.

While more research is needed to ascertain the viability of using CBD for treating ovarian cancer, preliminary research shows there is definite reason for continued study.  We anticipate seeing more studies examining the effects of CBD on cancer cells.

To read more about the study from Sullivan University, click here.

CBD Could Help Treat Diabetic Retinopathy

In a study performed by the Department of Pharmacology and Toxicology at the Medical College of Georgia, researchers studied the protective effects of cannabidiol (CBD) on rats with diabetic retinopathy.

One of the many complications of diabetes can be diabetic retinopathy.  Caused by damage to the blood vessels in the retina of the eye, diabetic retinopathy impairs eyesight and can possibly lead to blindness. In a study performed by the Department of Pharmacology and Toxicology at the Medical College of Georgia, researchers studied the protective effects of cannabidiol (CBD) on rats with diabetic retinopathy.  CBD is one of the main components of hemp and has been shown to have a regulatory effect on the body’s endocannabinoid system, as well as, a diverse pharmacological profile.

During the conducted study, rats were induced with diabetes and treated with CBD after 1, 2 or 4 weeks. The diabetes caused significant rises in oxidative stress, retinal neuronal cell death and vascular permeability; following CBD treatment, these symptoms were reduced. The CBD administered also prevented retinal cell death and vascular hyperpermeability, which is excessive leaking of fluid and proteins from the blood vessels. The combined results demonstrated that CBD could reduce neurotoxicity, inflammation and blood-retinal barrier breakdown in diabetic animals.

We look forward to reviewing more medical studies regarding CBD therapy and diabetes.  To read the study from the Medical College of Georgia, referenced above, please see here.